

Anti-infective formulations, relative cost, and ability to manipulate for enteral tube administration

Underlined agents have absorption nearly equivalent to IV

Antimicrobial Agent	Formulation	Relative Cost	Crush/Open?	Comments
Acyclovir	Capsule	\$\$\$	Yes	
	Tablet	\$		
	Suspension	\$\$		
	IV	\$\$		
<u>Amoxicillin</u>	Capsule	\$	Yes	Only the extended-release formulation should NOT be crushed
	Tablet	\$		
	Suspension	\$		
Ampicillin	IV	\$\$		
Amoxicillin/clavulanate	Tablet	\$	Yes	Only the extended-release formulation should NOT be crushed
	XR Tablet	\$		
	Suspension	\$		
Ampicillin/sulbactam	IV	\$\$		
Atovaquone	Suspension	\$\$	N/A	
<u>Azithromycin</u>	Tablet	\$	Yes	
	Suspension	\$\$		
	IV	\$		
Cefuroxime	Tablet	\$	Yes	Crushing tablet is associated with strong, persistent, bitter taste
	IV	\$\$		
Cephalexin	Capsule	\$	Yes	
	Tablet	\$		
	Suspension	\$\$		
Cefazolin	IV	\$		
<u>Ciprofloxacin (NF)</u>	Tablet	\$	Yes	Only the extended-release formulation should NOT be crushed
	Suspension	\$\$		
	IV	\$		
Clarithromycin	Tablet	\$	Yes	Only the extended-release formulation should NOT be crushed
	Suspension	\$\$		
<u>Clindamycin</u>	Capsule	\$	Yes	
	Suspension	\$\$		
	IV	\$\$		
Dapsone	Tablet	\$	Yes	

Antimicrobial Agent	Formulation	Relative Cost	Crush/Open?	Comments
<u>Delafloxacin (NF)</u>	Tablet	\$\$\$\$	Yes	
	IV	\$\$\$\$		
Dicloxacillin	Capsule	\$	Yes	
<u>Doxycycline</u>	Capsule	\$	Yes	Only the delayed-release formulation should NOT be crushed
	Tablet	\$		
	Suspension	\$		
	IV	\$\$		
Erythromycin	Capsule	\$\$	Yes	Formulations that are enteric coated should NOT be crushed. Crushing erythromycin ethyl succinate tablet is associated with poor taste
	Tablet	\$\$		
	Suspension	\$\$\$		
	IV	\$\$\$\$\$		
Ethambutol	Tablet	\$	Yes	
Fidaxomicin (NF)	Tablet	\$\$\$\$\$	Yes	
	Suspension	\$\$\$\$\$		
Famciclovir	Tablet	\$	Yes	
<u>Fluconazole</u>	Tablet	\$	Yes	
	Suspension	\$		
	IV	\$		
Flucytosine	Capsule	\$\$\$\$\$	Yes	
Fosfomycin (R)	Packet	\$\$\$	Yes	
<u>Isavuconazonium sulfate (R)</u>	Capsule	\$\$\$\$	No	
	IV	\$\$\$\$\$		
Isoniazid	Tablet	\$	Yes	
	Suspension	\$\$		
	IV	Not available		
Itraconazole	Capsule	\$	Yes	Crushing may result in changes to pharmacokinetic amorphous solid dispersion technology
	Suspension	\$\$		
Letermovir (R)	Tablet	\$\$\$\$\$	Yes	
	IV	\$\$\$\$\$		
<u>Levofloxacin</u>	Tablet	\$	Yes	
	Suspension	\$\$		
	IV	\$		
<u>Linezolid</u>	Tablet	\$	Yes	
	Suspension	\$\$\$\$		
	IV	\$\$		

Antimicrobial Agent	Formulation	Relative Cost	Crush/Open?	Comments
<u>Metronidazole</u>	Tablet	\$	Yes	
	Suspension	\$\$		
	IV	\$\$\$\$		
Minocycline	Capsule	\$	Yes	Only the extended-release formulation should NOT be crushed
	Tablet	\$		
	IV	\$\$\$\$\$		
Moxifloxacin (NF)	Tablet	\$	Yes	
	IV	\$\$		
Nitrofurantoin	Capsule	\$	Yes	Only the monohydrate/microcrystal capsule formulation (e.g., twice daily formulation) should NOT be opened/crushed
	Suspension	\$\$\$\$\$		
Oseltamivir	Capsule	\$	Yes	
	Suspension	\$\$		
Penicillin VK Penicillin G Potassium	Tablet	\$	Yes	
	Suspension	\$		
	IV	\$\$		
<u>Posaconazole (R)</u>	Tablet	\$\$\$	No	
	Suspension	\$\$\$\$		
	IV	\$\$\$\$\$		
Primaquine	Tablet	\$	Yes	
Pyrazinamide	Tablet	\$\$	Yes	
Pyrimethamine	Tablet	\$\$\$\$\$	Yes	
Ribavirin (R)	Capsule	\$	No	
	Tablet	\$		
	Suspension	Not available		
Rifabutin	Capsule	\$\$	Yes	
<u>Rifampin</u>	Capsule	\$	Yes	
	IV	\$\$\$		
Sulfadiazine	Tablet	\$\$\$	Yes	
<u>Trimethoprim/sulfamethoxazole</u>	Tablet	\$	Yes	
	Suspension	\$		
	IV	\$\$		

Antimicrobial Agent	Formulation	Relative Cost	Crush/Open?	Comments
Valacyclovir	Tablet	\$	Yes	
Valganciclovir	Tablet	\$	No	Hazardous substance – carcinogenic, mutagenic, and irritant potential, avoid direct contact with broken or crushed powder for oral solution
	Suspension	\$\$\$\$		
Ganciclovir	IV	\$\$\$		
Vancomycin	Capsule	\$	No	
	Suspension	\$\$		
<u>Voriconazole</u>	Tablet	\$	Yes	If crushing the tablet formulation, must utilize RxCrush
	Suspension	\$\$\$		
	IV	\$\$		
<p>NF = non-formulary, R = restricted, XR = extended-release, CSTD closed system transfer device</p> <p>Key: Inpatient acquisition costs, not including preparation or administration</p> <p>\$ < 10, \$\$ = \$10-49, \$\$\$ = \$50-99, \$\$\$\$ = \$100-199, \$\$\$\$\$ > \$200/day</p> <p><u>Underlined</u> agents have absorption nearly equivalent to IV</p>				

Document prepared by: Shownalyn Sunagawa, PharmD; October 2022

Reviewed by: Scott Bergman, PharmD, Emily Kreikemeier, PharmD, Trevor Van Schooneveld, MD, Medication Safety Committee, Medication Management Committee, Antimicrobial Stewardship Program

Selected References:

1. Lexi-comp. Wolters Kluwer. 2022.
2. Echaiz, TA. Oral Dosage Forms That Should Not Be Crushed 2020. Institute for Safe Medication Practices.
3. White R, Bradnam V. Handbook of Drug Administration Via Enteral Feeding Tubes, 3rd Edition. Pharmaceutical Press. 2015.
4. Adamsick ML, Elshaboury RH, Gift T, et al. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report. *Transpl Infect Dis.* 2019 Apr;21(2):e13048. doi: 10.1111/tid.13048. Epub 2019 Jan 29. PMID: 30636363.
5. Chen K, Cheng MP, Hammond SP, et al. Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation. *Blood Adv.* 2018;2(16):2159-2175.
6. Whelchel K, Zuckerman AD, Koren DE, et al. Crushing and Splitting Direct-Acting Antivirals for Hepatitis C Virus Treatment: A Case Series and Literature Review. *Open Forum Infectious Diseases.* 2021;8(11):ofab525.
7. Kennedy G, Osborn J, Flanagan S, et al. Stability of Crushed Tedizolid Phosphate Tablets for Nasogastric Tube Administration. *Drugs R D.* 2015 Dec;15(4):329-33. doi: 10.1007/s40268-015-0108-6. PMID: 26416654; PMCID: PMC4662946.
8. Henkin CC, Griener JC, Ten Eick AP. Stability of valganciclovir in extemporaneously compounded liquid formulations. *Am J Health Syst Pharm.* 2003 Apr 1;60(7):687-90. doi: 10.1093/ajhp/60.7.687. PMID: 12701551.
9. Dodds Ashley ES, Zaas AK, Fang AF, et al. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. *Antimicrob Agents Chemother.* 2007 Mar;51(3):877-80. doi: 10.1128/AAC.01263-06. Epub 2006 Dec 4. PMID: 17145785; PMCID: PMC1803130.
10. Dieringer TD, Schaenman JM, Davis MR. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules. *J Antimicrob Chemother.* 2022 Apr 27;77(5):1417-1423. doi: 10.1093/jac/dkac035. PMID: 35174391.